Biomarker ID | 1484 |
PMID | 25075250 |
Year | 2014 |
Biomarker | miR-219 |
Biomarker Basis | Expression Based |
Biomolecule | miRNA |
Source | Tissue |
Subjects | Humans |
Regulation | Downregulated in Metastatis (No Metastasis: 0.532 ± 0.028; Metastatis: 0.448 ± 0.029) |
Odds Ratio/Hazard Ratio/Relative Risk | NA |
Effect on Pathways | Pathways include: nucleoplasm; positive regulation of metabolic process; positive regulation of cellular metabolic process; DNA-binding transcription factor activity, RNA polymerase II-specific; anatomical structure morphogenesis |
Experiment | Metastatic Vs Non Metastatic Prostate Cancer |
Type of Biomarker | Prognostic |
Cohort | 215 samples were chosen for analysis. 204 were malignant and 11 were benign. 111 without metastatis and 80 with metastatis |
Senstivity | NA |
Specificity | NA |
AUC | NA |
Accuracy | NA |
Level Of Significance | p= 0.039 |
Method Used | In Situ hybridization (ISH) |
Clinical | No |
Remarks | Results for epithelial carcinoma cell study |
Clinical Trial Number | NA |
Degree Of Validity | Validated on independent patient dataset |
Technical Name | NA |